9 22 03 — Press Release Target Discovery Introduces First

9/22/03 - Press Release: Target Discovery Introduces First Product Line … Jeffrey N. Peterson, CEO UBS Global Life Sciences Conference 9/22/2003 … EOTrol™ Dynamic Coatings Open New Horizons for Electrophoretic Separations

Target Discovery, Inc. Ø Strategic targets … critical leverage points Ø Multidisciplinary team … innovative breakthroughs Ø Pragmatic, clear plan of attack … tiered objectives Ø Laser-like focus on priorities and execution

Pharma R&D Productivity Squeeze CO ST RE ST CO CO E PERSONALIZEDN VERY U TIM G DE PA R IN EST Optimize MEDICINE TENT T Rescue Lead Clinical Cannot Play the Same Old Game … Pre. Get on Leads Clinicals Approval EQUITY FOR UL clinicals M Formulary ARY MARKETS REIMBUR : $500 -800 M 11 -15 years SEMENT 3 X ICS” “OM ENTS PIPELINE !! INTM APPO DIS Target ?

From “Omics” … to “Knowmics” ™ v Bio. Information exploding … Ø Current technologies are bogged down Ø Much data is of low quality / utility … and too costly Ø Not converting to “Bio. Knowledge” v Key: Confirmed Biochemical Pathway confidence directs efficient development Ø Lower costs Ø Expedited approval

From “Omics” … to “Knowmics” ™ v Key: Confirmed Biochemical Pathway l Need High Quality Data Ø Complete – full horizon proteome and other “omics” Ø Precise – enable meaningful comparisons Ø Cost effective – affordable utility l Need efficient Systems Biology tools Ø Pathway Model generation – flexible alternatives Ø Computational Strategy – speed & complexity Ø Discover Optimized Correlation to high quality data New Breakthrough Technologies Required

From “Omics” … to “Knowmics” ™ v Bio. Information exploding … Ø Current technologies are bogged down Ø Much data is of low quality / utility … and too costly Ø Not converting to “Bio. Knowledge”

Discovery Biology Reveals the Pathway Discovery Biology Target Identification Interactional Proteomics Target Validation Metabolomics Target Selection Systems Biology Optimize Lead Target TDI Technologies Expressional Proteomics Leads Preclinicals $500 -800 M MDCE™ EOTrol™ IMLS™ IGEMS™ IDBEST™ Meta. SIRMS™ Path. Evolve™ Optimize Clinicals Approval 11 -15 years Get on Formulary

Intellectual Property Development US Patents and Applications Foreign Equivalent US 09/551937 US 6379971 US 6537432 US 09/513907 US 09/553424 Label Chemistry IMLS (issued 4/30/02) MDCE (issued 3/24/03) Databases Metabolomics (allowed) US 10/035349 Mass Defect Tags US 09/033303 IMLS Algorithm TDI 0003 TDI 0005 Trade Secret MS Sensitivity (provisional) Systems Biology / A. I. (provisional) Dynamic Coatings WO 00/63683 (pub. 10/01) National Phase WO 01/49951 (pub. 8/02) WO 01/49491 (pub. 8/02)

The Value of “Targets” v Value Proposition Deal Value Royalties l Gene Patent $1 -2 M 0 -2% l Putative Target (set) $1 -3 M ($5 -15 M) 1 -5% l Validated Target $10 -12 M 3 -7% l “Proven” Optimal Target $20 -200 M 5 -15% Ø All current drugs based on 600 known targets “Undiscovered Targets” Market: $10 B+ Ø 3, 000 to 15, 000 undiscovered new targets Source: Bio. Century, Bank of America, Price Waterhouse Coopers.

TDI Business/Revenue Model v Discovery Biology-Based Pharmaceuticals (Long-Term) l Forward integration & partnering of complementary technologies l Selected diseases & targets reserved for internal development v Pharmaceutical & Diagnostic Partnerships (Mid-Term) l l “Target” licenses - by tissue and disease Time-limited exclusivity then, shared access models Value-added extension into validation, modeling, selection Narrow band platform out-licensing to “target’ license clients v Early Commercialization Out-Licensing (Near-Term) l l EOTrol™ Dynamic capillary coatings IDBEST™ Differential display kits (possible protein chip/MS partner) IMLS™ Sequencing kits (possible MS instrument partner) IGEMS™ MS sensitivity enhancement (MS instrument partner)

TDI Discovery Biology Platform v Target Identification (Expressional Proteomics) l Complete proteome separation and quantitation Ø Multidimensional zero-EOF capillary electrophoresis (MDCE™) Ø Dynamic coatings for capillary EOF control (EOTrol™) l High speed protein identification Ø Inverted mass ladder sequencing (IMLS™) l Proprietary MS sensitivity breakthrough (IGEMS™) v Target Validation (Interactional Proteomics / Metabolomics) l Population screening using differential display on protein chips Ø Isotope differentiated binding energy shift tags (IDBEST™) l Confirmation by metabolomic flux determination in vivo Ø Metabolic flux stable isotope ratio mass spectrometry (Meta. SIRMS™) v Target Selection (Systems Biology) l Artificial intelligence for physiological model optimization and in silico target selection (Path. Evolve™)

Protein Expression: 2 -D Gels vs. MDCE™ E. coli Wheat Germ (CIEF/CGE) Key: Elimination of “EOF” US Patent Issued: MDCE™ at Low EOF Performance Measure 2 -D Gel MDCE™ 1 st Product: Proteome Dynamic Capillary Coatings Breadth of EOTrol™ 30% 100% Resolution Capacity (theory) 7, 000 >30, 000 Sensitivity (copies per cell) ≈105 <10 Quantitative Precision >20% <1% Dynamic Range 102 -3 105 -7 Automated Analysis No Yes

EOF Causes Resolution Loss in CE EOF Must Be Eliminated To Achieve High Resolution Separations Herr, A. E. et al. , Anal. Chem. , 72: 1053 -1057 (2000).

EOTrol™ Dynamic Coatings Introduced v Electrophoretic Separations Ø Capillary Electrophoresis Ø Microchannels v Performance Breakthrough or Optimizer: Ø Resolution Ø Throughput Ø Reproducibility v User-Selectable EOF Control Ø Normal or REVERSE Direction Ø High or Low - and Stable v p. H and Buffer Independent v New Separations Enabled - Cations! v Multiple Applications in 1 Capillary Ø Quick Strip for EOTrol™ Switches Ø No Capillary Change-Out! FREE DEMO PACK

The “Mass Defect” Elements in Proteins Ideal Mass Defect Labels Mass Defect (amu) = Monoisotopic Mass - Shift Tags+ #Neutrons) Isotope-Differentiated Binding Energy (#Protons (IDBEST™)

IDBEST™ Myoglobin Fragmentation b 1 -ion [81 Br]-b 1 -ion [79 Br]-b 1 -ion

Spectral Deconvolution of IMLS Labels Benefit: 100 X Speed & Cost Improvement Applicable to Any Biomolecule Key IP: Mass Defect Tags (Method & Composition) Algorithms (Deconvolution) Relative Abundance of 50: 50 Isotope Pairs Preserved Product: 3 rd Allows Qualification of IMLS Sequence Peaks IMLS™ Reagents & Software Label-GLS Label-GLSD

Expressional Proteomics - TDI CAPILLARY ELECTROPHORESIS First Dimension (Isoelectric Point) “N”th Dimension (Molecular Weight) Electropherogram p. I 1 LIF Detector Labeled Protein Sample Fraction Collection (each stage) Key Advantages: • Speed 100 – 1000 X • Precision 100 X • Sensitivity 100 X • Resolution 4 -5 X • Breadth of Proteome 3 X p. I 2 MW ESI-TOF Mass Spec p. I 3 Terminal Sequence Tag Algorithm MSGGFTA

Mass Spec Sensitivity Breakthrough 104 103 1 in 500 ions reach detector h detection (ppm) 102 101 100 IGEMS™ Run 2 10 -1 10 -2 10 -3 -4 10 Typical MS sensitivity Run 1 10 -3 10 -2 PEO Weight Concentration (g/L) 10 -1 100

TDI Discovery Biology Platform v Target Identification (Expressional Proteomics) l Complete proteome separation and quantitation Ø Multidimensional zero-EOF capillary electrophoresis (MDCE™) Ø Dynamic coatings for capillary EOF control (EOTrol™) l High speed protein identification Ø Inverted mass ladder sequencing (IMLS™) l Proprietary MS sensitivity breakthrough (IGEMS™) v Target Validation (Interactional Proteomics / Metabolomics) l Population screening using differential display on protein chips Ø Isotope differentiated binding energy shift tags (IDBEST™) l Confirmation by metabolomic flux determination in vivo Ø Metabolic flux stable isotope ratio mass spectrometry (Meta. SIRMS™)

IDBEST™ Fast / Precise Differential Display Healthy Tissue Proteins v Current: Protein Chip & MS Diseased Tissue Proteins • Comparison of 2 spots [ C]- • Precision: > 50% std. dev. C]Benefit: 5 X Precision Improvement [12 Mass Defect Tag Bind to Capture Surface Key IP: 13 Mass Defect Eliminates ICAT™ Tag Mix cleanup & false pos/neg Mass Defect Tags (Method & Composition) Algorithms (Deconvolution) Digest and MS 2 nd Product: IDBEST™ Reagents & Software Peptides Identity by Tandem MS

Metabolic Flux Confirmation with SIRMS FEED: 50% [13 C or 15 N]-metabolite 50% [12 C or 14 N]-metabolite v Stable Isotope Ratio MS of metabolites (Meta. SIRMS™) l Direct metabolic flux measure in vivo l Track ratios & kinetics down branch points l Estimate pool sizes Metabolomics in Early Emergence Extract to FTICR-MS TDI’s Patent Has Been Allowed v Validate protein involvement in pathway of interest v HTS for ADME and Efficacy Studies v Metabolite stoichiometric identification using FTICR-MS 12 C 13 C Deduce kinetics

TDI Discovery Biology Platform v Target Identification (Expressional Proteomics) l Complete proteome separation and quantitation Ø Multidimensional zero-EOF capillary electrophoresis (MDCE™) Ø Dynamic coatings for capillary EOF control (EOTrol™) l High speed protein identification Ø Inverted mass ladder sequencing (IMLS™) l Proprietary MS sensitivity breakthrough (IGEMS™) v Target Validation (Interactional Proteomics / Metabolomics) l Population screening using differential display on protein chips Ø Isotope differentiated binding energy shift tags (IDBEST™) l Confirmation by metabolomic flux determination in vivo Ø Metabolic flux stable isotope ratio mass spectrometry (Meta. SIRMS™) v Target Selection (Systems Biology) l Artificial intelligence for physiological model optimization and in silico target selection (Path. Evolve™)

Systems Biology Paradigm & Problems PHYSIOLOGY MODULES (subroutines of dimensionless algebraic & differential equations) Stiff Differential Equations requiring Numerical Integration Integrator Kernel Computational Workload Mine for Rates and Concentrations Difference Data Enzymes -Michaelis. Menton -Ping-Pong Protein Expression Transport -Passive -Facilitated -Active Transcription -Convection -Diffusion Linearized Equilibria -Constitutive -Repression/ Activation Intertissue Transport Model Biologist’s Consensus Flexibility Accumulation -Absorption -Fluid Pools (rates and concentrations) Gene Expression Equilibria -Binding -Phase -Reactional PHYSIOLOGY DATABASES SYSTEM MODEL Physio. Tool ® 2000 Target Discovery, Inc. /All Rights Reserved Human Mind Complexity Limits Compare Predictions to Experimental Data Iterate? … Data Quality Metabolism

TDI Systems Biology: Path. Evolve™ v Unit Operations strategy –math models for biological process elements v Artificial intelligence algorithms … from VLSI IC design process l Accelerates exploration of alternative pathway models l Accelerates convergence on optimal model … by correlation to data l Accommodates all designated data and design constraints v Unique computational strategy … from process control industry l Works directly with differential display data formats Ø Gene. Chip™, ICAT™, IDBEST™, Meta. SIRMS™ and SIR-NMR v Up to 1012 acceleration potential for convergence on optimum models v Optimized models provide confidence and direction l Allow sensitivity analysis for target selection l Enables in silico experimentation for target / lead / clinical optimization l Comprehensive approach eliminates subjective biases and assumptions

TDI Team v Senior Management / Founders l CEO: Jeffrey N. Peterson Ø Abbott Laboratories (CEO/GM Abbott South Africa) Ø General Electric (Engineered Materials & Plastics Groups) Ø MIT (MSChem. E, BSChem. E) l CSO: Dr. Luke V. Schneider Ø SRI (Stanford Research Institute) International § Dir. Technology Development § Dir. Combinatorial Methods Center § Dir. Upconverting Phosphor Diagnostics § Winner, Monsanto Million Dollar Challenge Ø Du. Pont (Central R&D, Coatings) Ø Princeton (Ph. DChem. E, MAChem. E) Ø USF (MSEChem. E, BSESChem. E, BABiology)

TDI Team v Scientific Advisory Board l Dr. Juan Santiago (Stanford) l Dr. Jack Shively (City of Hope) l Dr. Alan Smith (Stanford PAN Facility) l Dr. Evan Williams (UC Berkeley) l Dr. Leon Yengoyan (San Jose State) v Board of Directors l Jeffrey N. Peterson, CEO l Dr. Luke V. Schneider, CSO l Clayton A. Struve (CEO CSS, ex-MD Swiss. Bank, O’Connor) l Steven M. Rauscher (CEO Genome Therapeutics, Americas. Doctor. com, Affiliated Research Centers, Abbott)

TDI Growth Trajectory $7 M A Round (’ 99–’ 03) Close 2 1 st NIH Grant Close 0 0 EOTrol™ Introduced 1 st TDI Commercial Revenues $3 -7 M B Round Close 3 2 0 IMLS™ Intro IDBEST™ Intro IGEMS™ Demonstration 0 4 IGEMS™ Out. Licensed 2 MDCE™ Intro 1 st Full Discovery Biology Partnership 0 0 Optional C Round Growth Acceleration Decision 5

Target Discovery, Inc. From Omics to Knowmics™ Ø Strategic targets … critical leverage points Ø Multidisciplinary, innovative breakthrough technologies Ø Pragmatic, clear plan of attack … tiered objectives Ø Laser-like focus on priorities and execution

www. targetdiscovery. com